Exome Asset Management 13F annual report
Exome Asset Management is an investment fund managing more than $115 billion ran by Brianne Shergill. There are currently 50 companies in Mrs. Shergill’s portfolio. The largest investments include Eli Lilly & Co and Merus N.V, together worth $15.6 billion.
$115 billion Assets Under Management (AUM)
As of 7th August 2024, Exome Asset Management’s top holding is 9,700 shares of Eli Lilly & Co currently worth over $8.78 billion and making up 7.6% of the portfolio value.
In addition, the fund holds 74,000 shares of Merus N.V worth $6.79 billion, whose value grew 21.5% in the past six months.
The third-largest holding is Sarepta Therapeutics Inc worth $5.2 billion and the next is TG Therapeutics Inc worth $4.48 billion, with 251,600 shares owned.
Currently, Exome Asset Management's portfolio is worth at least $115 billion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
Careers at Exome Asset Management
The Exome Asset Management office and employees reside in New York, New York. According to the last 13-F report filed with the SEC, Brianne Shergill serves as the Chief Compliance Officer at Exome Asset Management.
Recent trades
In the most recent 13F filing, Exome Asset Management revealed that it had opened a new position in
Merus N.V and bought 74,000 shares worth $6.79 billion.
This means they effectively own approximately 0.1% of the company.
Merus N.V makes up
8.2%
of the fund's Health Care sector allocation and has grown its share price by 120.9% in the past year.
The investment fund also strengthened its position in TG Therapeutics Inc by buying
21,300 additional shares.
This makes their stake in TG Therapeutics Inc total 251,600 shares worth $4.48 billion.
TG Therapeutics Inc soared 91.3% in the past year.
On the other hand, there are companies that Exome Asset Management is getting rid of from its portfolio.
Exome Asset Management closed its position in BeiGene Ltd on 14th August 2024.
It sold the previously owned 36,800 shares for $5.76 billion.
Brianne Shergill also disclosed a decreased stake in Cigna by 0.2%.
This leaves the value of the investment at $4.03 billion and 12,200 shares.
One of the smallest hedge funds
The two most similar investment funds to Exome Asset Management are Tenzing Global Management and M3 Advisory. They manage $115 billion and $115 billion respectively.
Brianne Shergill investment strategy
Exome Asset Management’s portfolio is diversified across 2 sectors.
Currently, their heaviest sector is Health Care — making up 72.3% of
the total portfolio value.
The fund focuses on investments in the United States as
52.0% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are large-cap stocks.
Stocks with a size of more than $10 billion in market cap make up
10% of the total holdings value.
On the other hand, small-cap stocks make up only 6.0% of the portfolio.
The average market cap of the portfolio companies is close to $12.7 billion.
The complete list of Exome Asset Management trades based on 13F SEC filings
These positions were updated on August 14th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Eli Lilly & Co |
No change
9,700
|
$8,782,186,000 | 7.65% |
| Merus N.V |
Opened
74,000
|
$6,791,730,000 | 5.91% |
| BeiGene Ltd |
Closed
36,800
|
$5,755,152,000 | |
| Sarepta Therapeutics Inc |
Opened
32,900
|
$5,198,200,000 | 4.53% |
| Alpine Immune Sciences Inc |
Closed
117,000
|
$4,637,880,000 | |
| TG Therapeutics Inc |
9.25%
251,600
|
$4,475,964,000 | 3.90% |
| Wave Life Sciences Ltd. |
Opened
496,635
|
$4,406,264,000 | 3.84% |
| Cigna Group (The) |
20.26%
12,200
|
$4,032,954,000 | 3.51% |
| Corbus Pharmaceuticals Hldgs |
3.48%
84,790
|
$3,836,748,000 | 3.34% |
| Insmed Inc |
20.78%
56,800
|
$3,805,600,000 | 3.31% |
| AMGEN Inc. |
Opened
11,800
|
$3,686,910,000 | 3.21% |
| Travere Therapeutics Inc |
22.32%
443,379
|
$3,644,576,000 | 3.17% |
| Avidity Biosciences, Inc. |
Closed
135,169
|
$3,449,513,000 | |
| Madrigal Pharmaceuticals Inc |
36.71%
10,800
|
$3,025,728,000 | 2.63% |
| Celldex Therapeutics Inc. |
Closed
71,100
|
$2,984,067,000 | |
| Avadel Pharmaceuticals plc |
Opened
209,092
|
$2,939,834,000 | 2.56% |
| Dexcom Inc |
4.43%
25,928
|
$2,939,716,000 | 2.56% |
| Geron Corp. |
Closed
886,800
|
$2,926,440,000 | |
| Autolus Therapeutics plc |
Opened
839,472
|
$2,921,362,000 | 2.54% |
| Aerovate Therapeutics Inc |
Closed
98,485
|
$2,912,201,000 | |
| Intuitive Surgical Inc |
No change
6,358
|
$2,828,356,000 | 2.46% |
| Morphosys AG |
Closed
154,800
|
$2,808,072,000 | |
| Dr Reddys Labs Ltd |
57.79%
36,300
|
$2,765,698,000 | 2.41% |
| Disc Medicine Inc |
Opened
61,000
|
$2,749,270,000 | 2.39% |
| Ascendis Pharma A/S |
Opened
20,000
|
$2,727,600,000 | 2.37% |
| Kura Oncology Inc |
Opened
131,742
|
$2,712,568,000 | 2.36% |
| Krystal Biotech Inc |
Closed
14,700
|
$2,615,571,000 | |
| Biohaven Ltd |
Opened
90,189
|
$2,539,684,000 | 2.21% |
| Masimo Corp |
Opened
19,800
|
$2,493,612,000 | 2.17% |
| Centessa Pharmaceuticals Plc |
No change
274,900
|
$2,482,348,000 | 2.16% |
| Tarsus Pharmaceuticals, Inc. |
Closed
66,300
|
$2,410,005,000 | |
| Guardant Health Inc |
No change
79,000
|
$2,281,520,000 | 1.99% |
| Cabaletta Bio Inc |
Opened
300,200
|
$2,245,496,000 | 1.96% |
| Arvinas Inc |
Opened
82,400
|
$2,193,488,000 | 1.91% |
| Inozyme Pharma, Inc. |
Closed
273,413
|
$2,094,344,000 | |
| Natera Inc |
No change
18,650
|
$2,019,608,000 | 1.76% |
| BridgeBio Pharma Inc |
61.67%
78,907
|
$1,998,714,000 | 1.74% |
| Rhythm Pharmaceuticals Inc. |
Closed
45,603
|
$1,975,978,000 | |
| Fulcrum Therapeutics Inc |
Opened
302,700
|
$1,876,740,000 | 1.63% |
| Exact Sciences Corp. |
Closed
26,700
|
$1,843,902,000 | |
| Cytokinetics Inc |
Closed
26,008
|
$1,823,421,000 | |
| Apellis Pharmaceuticals Inc |
Opened
46,900
|
$1,799,084,000 | 1.57% |
| Regenxbio Inc |
Closed
84,470
|
$1,779,783,000 | |
| Biogen Inc |
Closed
8,200
|
$1,768,166,000 | |
| Ocular Therapeutix Inc |
Closed
193,600
|
$1,761,760,000 | |
| Agios Pharmaceuticals Inc |
Closed
59,902
|
$1,751,534,000 | |
| Alphatec Holdings Inc |
Opened
162,100
|
$1,693,946,000 | 1.47% |
| Penumbra Inc |
Closed
7,353
|
$1,641,043,000 | |
| Olema Pharmaceuticals, Inc. |
Closed
143,400
|
$1,623,288,000 | |
| Establishment Labs Holdings Inc |
Opened
26,000
|
$1,599,530,000 | 1.39% |
| Arrowhead Pharmaceuticals In |
Closed
55,700
|
$1,593,020,000 | |
| AbCellera Biologics Inc. |
Opened
514,900
|
$1,524,104,000 | 1.33% |
| Zai Lab Ltd |
32.77%
86,700
|
$1,502,510,000 | 1.31% |
| Terns Pharmaceuticals Inc |
Closed
227,821
|
$1,494,506,000 | |
| Marinus Pharmaceuticals Inc |
Closed
163,100
|
$1,474,424,000 | |
| Inari Med Inc |
Closed
30,100
|
$1,444,198,000 | |
| Intra-Cellular Therapies Inc |
Closed
20,300
|
$1,404,760,000 | |
| Pliant Therapeutics, Inc. |
Opened
124,000
|
$1,333,000,000 | 1.16% |
| Shockwave Med Inc |
Closed
4,000
|
$1,302,520,000 | |
| Rezolute Inc |
Opened
282,400
|
$1,214,320,000 | 1.06% |
| Alvotech |
Opened
99,000
|
$1,203,840,000 | 1.05% |
| Regulus Therapeutics Inc |
Closed
402,504
|
$1,159,212,000 | |
| Gossamer Bio, Inc. |
Opened
1,127,699
|
$1,015,944,000 | 0.88% |
| Enliven Therapeutics Inc |
Closed
57,635
|
$1,013,800,000 | |
| Elevation Oncology Inc |
No change
369,322
|
$997,170,000 | 0.87% |
| Ventyx Biosciences Inc |
Closed
163,922
|
$901,571,000 | |
| Procaps Group Sa |
Opened
129,301
|
$877,428,000 | 0.76% |
| Ultragenyx Pharmaceutical In |
Closed
17,800
|
$831,082,000 | |
| Syros Pharmaceuticals Inc. |
Opened
159,175
|
$821,344,000 | 0.72% |
| Quanterix Corp |
No change
59,650
|
$787,976,000 | 0.69% |
| Q32 Bio Inc |
32.54%
43,865
|
$787,376,000 | 0.69% |
| VYNE Therapeutics Inc. |
14.92%
353,434
|
$696,264,000 | 0.61% |
| Pmv Pharmaceuticals Inc |
Opened
358,400
|
$580,608,000 | 0.51% |
| Aprea Therapeutics, Inc. |
Opened
137,174
|
$558,298,000 | 0.49% |
| Adagene Inc |
2.90%
150,876
|
$461,832,000 | 0.40% |
| I-Mab |
16.69%
271,400
|
$453,238,000 | 0.39% |
| Hillevax Inc |
Opened
18,000
|
$260,280,000 | 0.23% |
| Sagimet Biosciences Inc |
16.75%
50,700
|
$173,394,000 | 0.15% |
| Pacific Biosciences Calif In |
No change
75,300
|
$103,162,000 | 0.09% |
| AvroBio Inc |
Closed
61,135
|
$78,253,000 | |
| No transactions found | |||
| Showing first 500 out of 80 holdings | |||
Hedge funds similar to Exome Asset Management
- Gerber
- Navpoint
- Western Standard
- Davis Capital Management
- Sound Strategies
- Lam Group, Inc
- Vienna Asset Management
- Tenzing Global Management
- M3 Advisory
- Meixler Investment Management
- Opinicus Capital, Inc
- Kingdom
- Vector Capital Management, L.P.
- Traction Partners